Concert Wealth Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Concert Wealth Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Hold	0	–	–	–	120
2016 Q3	–	Sell	-27,404	Closed	-$1.13M	–	190
2016 Q2	$1.01M	Buy	27,404 +477	+2%	+$18.7K	0.14%	204
2016 Q1	$1.03M	Buy	+26,927	New	+$1.05M	0.14%	191
2015 Q4	–	Sell	-24,907	Closed	-$1.14M	–	732
2015 Q3	$1.14M	Buy	+24,907	New	+$1.39M	0.15%	167
2015 Q2	–	Hold	0	–	–	–	158
2015 Q1	–	Hold	0	–	–	–	92
2014 Q4	–	Hold	0	–	–	–	162
2014 Q3	–	Hold	0	–	–	–	147
2014 Q2	–	Sell	-19,607	Closed	-$794K	–	182
2014 Q1	$789K	Buy	+19,607	New	+$839K	0.1%	183
2013 Q4	–	Sell	-18,644	Closed	-$661K	–	560
2013 Q3	$661K	Buy	+18,644	New	+$617K	0.09%	196
2013 Q2	–	Hold	0	–	–	–	206

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SAM

SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Concert Wealth Management's PBE Position: Q4 2016 in Review

Concert Wealth Management held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q4 2016 at 0 shares worth $1.08M. The position accounts for 0.24% of the portfolio, ranked #120.

Concert Wealth Management first reported a position in PBE in Q3 2013 and has held it in 5 quarters since. The position peaked at $1.14M in Q3 2015. 68 funds tracked by Wall St. Rank hold PBE as of Q4 2016.

Concert Wealth Management held 0 shares of Invesco Biotechnology & Genome ETF worth $1.08M as of Q4 2016.
Concert Wealth Management left its Invesco Biotechnology & Genome ETF share count unchanged in Q4 2016.
Invesco Biotechnology & Genome ETF made up 0.24% of Concert Wealth Management's portfolio in Q4 2016, its #120 holding.
Concert Wealth Management first reported a position in Invesco Biotechnology & Genome ETF in Q3 2013 and has held it in 5 quarters since.
Concert Wealth Management's Invesco Biotechnology & Genome ETF position peaked at $1.14M in Q3 2015.
68 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2016.

Based on Concert Wealth Management's 13F filing for Q4 2016, filed 10 Feb 2017.